80 related articles for article (PubMed ID: 23940730)
21. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Cholongitas E; Mamou C; Rodríguez-Castro KI; Burra P
Transpl Int; 2014 Oct; 27(10):1039-49. PubMed ID: 24943720
[TBL] [Abstract][Full Text] [Related]
22. Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review.
Sgourakis G; Dedemadi G
World J Gastroenterol; 2014 Aug; 20(31):10703-14. PubMed ID: 25152574
[TBL] [Abstract][Full Text] [Related]
23. Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma.
Xing T; Huang L; Yu Z; Zhong L; Wang S; Peng Z
PLoS One; 2013; 8(8):e71251. PubMed ID: 23940730
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive comparison of three different immunosuppressive regimens for liver transplant patients with hepatocellular carcinoma: steroid-free immunosuppression, induction immunosuppression and standard immunosuppression.
Liu YY; Li CP; Huai MS; Fu XM; Cui Z; Fan LL; Zhang S; Liu Y; Ma J; Li G; Shen ZY
PLoS One; 2015; 10(3):e0120939. PubMed ID: 25816221
[TBL] [Abstract][Full Text] [Related]
25. Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation.
Lee JY; Kim YH; Yi NJ; Kim HS; Lee HS; Lee BK; Kim H; Choi YR; Hong G; Lee KW; Suh KS
Clin Mol Hepatol; 2014 Jun; 20(2):192-203. PubMed ID: 25032186
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of a Steroid-Free Immunosuppressive Regimen after Liver Transplantation for Hepatocellular Carcinoma.
Wei Q; Xu X; Wang C; Zhuang R; Zhuang L; Zhou L; Xie H; Wu J; Zhang M; Shen Y; Wang W; Zheng S
Gut Liver; 2016 Jul; 10(4):604-10. PubMed ID: 27074818
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
Liu CL; Fan ST; Lo CM; Chan SC; Ng IO; Lai CL; Wong J
Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
[TBL] [Abstract][Full Text] [Related]
28. Early steroids after pediatric liver transplantation protect against T-cell-mediated rejection: Results from the ChilSFree study.
Goldschmidt I; Chichelnitskiy E; Götz J; Rübsamen N; Karch A; Jäger V; Kelly D; Lloyd C; Debray D; Girard M; d'Antiga L; di Giorgio A; Hierro L; Pawlowska J; Klaudel-Dreszler M; McLin V; Korff S; Falk C; Baumann U
Liver Transpl; 2024 Mar; 30(3):288-301. PubMed ID: 37678230
[TBL] [Abstract][Full Text] [Related]
29. Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010.
Hu Z; Zhou J; Wang H; Zhang M; Li S; Huang Y; Wu J; Li Z; Zhou L; Zheng S
PLoS One; 2013; 8(4):e61620. PubMed ID: 23613886
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma.
Menon KV; Hakeem AR; Heaton ND
Aliment Pharmacol Ther; 2013 Feb; 37(4):411-9. PubMed ID: 23278125
[TBL] [Abstract][Full Text] [Related]
31. Initial immunosuppression with or without basiliximab: a comparative study.
Martín-Mateos RM; Graus J; Albillos A; Arocena C; Rodríguez Gandía MA; Blesa C; García-Hoz F; García González M; García-Alonso FJ; Bárcena R
Transplant Proc; 2012 Nov; 44(9):2570-2. PubMed ID: 23146457
[TBL] [Abstract][Full Text] [Related]
32. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.
Welker MW; Bechstein WO; Zeuzem S; Trojan J
Transpl Int; 2013 Feb; 26(2):109-18. PubMed ID: 22994652
[TBL] [Abstract][Full Text] [Related]
33. Hepatocellular carcinoma: focus on different aspects of management.
Waly Raphael S; Yangde Z; Yuxiang C
ISRN Oncol; 2012; 2012():421673. PubMed ID: 22655206
[TBL] [Abstract][Full Text] [Related]
34. The relationship between recurrences and immunosuppression on living donor liver transplantation for hepatocellular carcinoma.
Miyagi S; Kawagishi N; Sekiguchi S; Akamatsu Y; Sato K; Takeda I; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2012 Apr; 44(3):797-801. PubMed ID: 22483499
[TBL] [Abstract][Full Text] [Related]
35. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
Klintmalm GB; Davis GL; Teperman L; Netto GJ; Washburn K; Rudich SM; Pomfret EA; Vargas HE; Brown R; Eckhoff D; Pruett TL; Roberts J; Mulligan DC; Charlton MR; Heffron TG; Ham JM; Douglas DD; Sher L; Baliga PK; Kinkhabwala M; Koneru B; Abecassis M; Millis M; Jennings LW; Fasola CG
Liver Transpl; 2011 Dec; 17(12):1394-403. PubMed ID: 21850690
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C.
Walter SR; Thein HH; Gidding HF; Amin J; Law MG; George J; Dore GJ
J Gastroenterol Hepatol; 2011 Dec; 26(12):1757-64. PubMed ID: 21615789
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
